on Monday overwhelmingly voted to approve the takeover of
New River Pharmaceuticals
A tender offer for New River shares, which started March 2, expires at midnight on April 17. The deal is worth $2.6 billion, or $64 a share.
The acquisition gives Britain's Shire full control over Vyvanse, a treatment for attention deficit hyperactivity disorder, which was developed by New River. Shire signed a marketing agreement with New River in 2005.
Shire made the offer for New River on Feb. 20, three days before the Food and Drug Administration approved Vyvanse. Shire sells two other ADHD drugs, Adderall XR and Daytrana. It expects to hear from the FDA in the coming months on applications for two others.